In a landmark moment for its oncology ambitions, GSK has secured FDA approval for Jideytro (zidesamtinib) as the first ...
While the White House focused its initial Section 232 pharmaceutical tariffs on branded drugs, generics makers—who supply the ...
Aiming to bolster ivonescimab’s case ahead of a key FDA decision, Summit Therapeutics has provided updated overall survival ...
The FDA has called out Sanofi’s promotion of respiratory syncytial virus (RSV) antibody Beyfortus in a new untitled letter, ...
A U.K. marketing watchdog has reprimanded Sanofi for using “a highly misleading interpretation of data” to make disparaging ...
Less than a month after Ionis Pharmaceuticals scored an FDA expansion for Tryngolza to become the first drug to specifically ...
Novartis' CEO remains unfazed by the threat of a newly approved oral PCSK9 inhibitor in Merck & Co.’s Lipfendra, doubling ...
Amgen has agreed to a $74 million settlement with investors who allege that the company hid a massive U.S. tax bill from the ...
Novo Nordisk has accused Eli Lilly of running ad campaigns containing “deliberately false” messages that mislead the public ...
Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has ...
Following an inspection earlier this year that yielded a Form 483, Indian generics juggernaut Alembic Pharmaceuticals has ...
South Korean contract manufacturer Samsung Biologics hopes to tap into the booming peptide production and weight loss market with plans to buy out Switzerland-based CDMO PolyPeptide for 1.46 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results